Gapping down
In reaction to disapointing earnings/guidance: RGSE -14.9%, LEJU -9.3%, YOKU -8.2%, TEDU -7.4%, JASO -7.4%, LZB -3.9%, SJM -3.3%, LOW -3.2%, CRH -2%, TGT -1.5%, MBT -1%,.
Select EU related names showing strength: PT -1.6%, ALU -1.2%, MT -1.1%, TEF -1%, SAN -1%, TEF -1%, DB -0.8%.
Select solar names trading lower in sympathy with JASO earnings: TSL -2.7%, YGE -1.3%, JKS -1.2%, SPWR -1%, CSIQ -0.4%.
Other news: NBY -32.8% (announces its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis), JRJC -7.3% (still checking), LOCO -2.3% (cont weakness), BUD -1.3% (following Carlsberg/Heineken earnings overseas), RDS.A -1% (still checking), ABB -0.9% (divesting business unit).
Analyst comments: RBC -1% (downgraded to Neutral from Buy at Longbow), THOR -0.9% (target lowered to $28 at WallachBeth).
In reaction to disapointing earnings/guidance: RGSE -14.9%, LEJU -9.3%, YOKU -8.2%, TEDU -7.4%, JASO -7.4%, LZB -3.9%, SJM -3.3%, LOW -3.2%, CRH -2%, TGT -1.5%, MBT -1%,.
Select EU related names showing strength: PT -1.6%, ALU -1.2%, MT -1.1%, TEF -1%, SAN -1%, TEF -1%, DB -0.8%.
Select solar names trading lower in sympathy with JASO earnings: TSL -2.7%, YGE -1.3%, JKS -1.2%, SPWR -1%, CSIQ -0.4%.
Other news: NBY -32.8% (announces its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis), JRJC -7.3% (still checking), LOCO -2.3% (cont weakness), BUD -1.3% (following Carlsberg/Heineken earnings overseas), RDS.A -1% (still checking), ABB -0.9% (divesting business unit).
Analyst comments: RBC -1% (downgraded to Neutral from Buy at Longbow), THOR -0.9% (target lowered to $28 at WallachBeth).